ATAI News & Analysis
4 articles
Market Mood
Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
Eli Lilly has announced its acquisition of AtaiBeckley for up to $3.8 billion, indicating a shift in Big Pharma's approach to psychedelic drugs for mental health. This acquisition follows positive clinical trial results for psychedelics, including Atai's BPL-003, a synthetic form of 5-MeO-DMT, currently in Phase 3 trials. The FDA has granted BPL-003 Breakthrough Therapy Designation, expediting its development for treatment-resistant depression, which affects around four million Americans. Analysts estimate that success in Phase 3 trials could open up a $1-2 billion market opportunity in this sector, signaling potential growth for investors interested in biotech innovations in mental health treatments.
Read More: Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
AtaiBeckley (ATAI) Included in Russell Indices Effective June 29
AtaiBeckley N.V. (NASDAQ: ATAI) announced on June 25 that it will be included in the Russell 2000 and Russell 3000 indices starting June 29. This reconstitution is significant as over $12 trillion in assets are tied to these benchmarks. Following this news, Canaccord Genuity raised its price target for ATAI from $15 to $17, indicating an upside potential of over 227%. The company is also advancing towards Phase 3 development for major depressive disorder after concluding dosing for its Phase 2 Elumina trial. This inclusion in major indices could enhance visibility and trading volume for ATAI shares, impacting investor interest.
Read More: AtaiBeckley (ATAI) Included in Russell Indices Effective June 29
Atai Life Sciences (ATAI) Price Target Raised to $17 on MDD Plans
Canaccord Genuity has increased its price target for Atai Life Sciences (ATAI) to $17, citing the company's plans related to Major Depressive Disorder (MDD). This adjustment reflects a positive outlook on Atai's potential developments in treating MDD. The forecast implies a significant anticipated market value and suggests investor confidence in the company's strategies. The upward revision could attract more investors, affecting the stock’s performance in the market.
Read More: Atai Life Sciences (ATAI) Price Target Raised to $17 on MDD Plans
AtaiBeckley Inc. (ATAI) Target Price $25 with 561.38% Upside Potential
AtaiBeckley Inc. (ATAI) maintains a Buy rating from H.C. Wainwright with a price target of $25, indicating a potential upside of 561.38%. This valuation follows a management discussion on June 2 about BPL-003, a treatment for depression currently in Phase 3 trials. Furthermore, the company has launched a Patient Impact Grant Program, providing three $20,000 grants aimed at enhancing mental health outcomes. As a clinical-stage biopharmaceutical company founded in 2018, ATAI is focused on developing mental health treatments in North America and Europe.
Read More: AtaiBeckley Inc. (ATAI) Target Price $25 with 561.38% Upside Potential